BRVE

Braveheart Bio, Inc. - Common Stock (BRVE)

About Braveheart Bio, Inc. - Common Stock (BRVE)

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

Details

Daily high

$28.74

Daily low

$26.54

Price at open

$28.12

52 Week High

$32.00

52 Week Low

$18.00

Market cap

2.4B

Dividend yield

Volume

283,592

Avg. volume

295,919

P/E ratio

Braveheart Bio, Inc. - Common Stock News